Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer

키워드

참고문헌 (66)

1. 정규원, "Cancer Statistics in Korea: Incidence, Mortality, Survival, and Prevalence in 2012", Cancer Research and Treatment, 47(2), pp.127~141 (2015), 대한암학회[DOI]
2. Watanabe T, "Japanese Society for Cancer of the Colon and Rectum(JSCCR)guidelines 2010 for the treatment of colorectal cancer", Int J Clin Oncol, 17, pp.1~29 (2012)
3. Andre T, "Oxaliplatin, fluorouracil, and leucovorin as adjuvant treatment for colon cancer", N Engl J Med, 350, pp.2343~2351 (2004)
4. Seo SI, "Comparison of recurrence patterns between ≤5 years and >5 years after curative operations in colorectal cancer patients", J Surg Oncol, 108, pp.9~13 (2013)
5. Sobrero AF, "Fluorouracil in colorectal cancer : a tale of two drugs : implications for biochemical modulation", J Clin Oncol, 15, pp.368~381 (1997)
6. "Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: evidence in terms of response rate. Advanced Colorectal Cancer Meta-Analysis Project", J Clin Oncol, 10, pp.896~903 (1992)
7. de Gramont A, "Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer : a French intergroup study", J Clin Oncol, 15, pp.808~815 (1997)
8. de Gramont A, "Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer", J Clin Oncol, 18, pp.2938~2947 (2000)
9. Douillard JY, "Irinotecan combined with fluorouracil compared with fluorouracil alone as first-line treatment for metastatic colorectal cancer : a multicentre randomised trial", Lancet, 355, pp.1041~1047 (2000)
10. Tournigand C, "FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer : a randomized GERCOR study", J Clin Oncol, 22, pp.229~237 (2004)
11. Hoff PM, "Comparison of oral capecitabine versus intravenous fluorouracil plus leucovorin as first-line treatment in 605 patients with metastatic colorectal cancer : results of a randomized phase III study", J Clin Oncol, 19, pp.2282~2292 (2001)
12. Van Cutsem E, "Oral capecitabine compared with intravenous fluorouracil plus leucovorin in patients with metastatic colorectal cancer : results of a large phase III study", J Clin Oncol, 19, pp.4097~4106 (2001)
13. Kwakman JJM, "Randomized phase III trial of S-1 versus capecitabine in the first-line treatment of metastatic colorectal cancer : SALTO study by the Dutch Colorectal Cancer Group", Ann Oncol, 28, pp.1288~1293 (2017)
14. Mayer RJ, "Randomized trial of TAS-102 for refractory metastatic colorectal cancer", N Engl J Med, 372, pp.1909~1919 (2015)
15. Cassidy J, "Randomized phase III study of capecitabine plus oxaliplatin compared with fluorouracil", folinic acid plus oxaliplatin as firstline therapy for metastatic colorectal cancer, 2008, pp.26, 2006~2012
16. Falcone A, "Phase III trial of infusional fluorouracil, leucovorin, oxaliplatin, and irinotecan(FOLFOXIRI)compared with infusional fluorouracil, leucovorin, and irinotecan(FOLFIRI)as first-line treatment for metastatic colorectal cancer : the Gruppo Oncologico Nord Ovest", J Clin Oncol, 25, pp.1670~1676 (2007)
17. Hurwitz H, "Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer", N Engl J Med, 350, pp.2335~2342 (2004)
18. Passardi A, "Effectiveness of bevacizumab added to standard chemotherapy in metastatic colorectal cancer : final results for first-line treatment from the ITACa randomized clinical trial", Ann Oncol, 26, pp.1201~1207 (2015)
19. Stathopoulos GP, "Treatment of colorectal cancer with and without bevacizumab : a phase III study", Oncology, 78, pp.376~381 (2010)
20. Cunningham D, "Bevacizumab plus capecitabine versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer(AVEX) : an open-label, randomised phase 3 trial", Lancet Oncol, 14, pp.1077~1085 (2013)
21. Saltz LB, "Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer : a randomized phase III study", J Clin Oncol, 26, pp.2013~2019 (2008)
22. Tebbutt NC, "Capecitabine, bevacizumab, and mitomycin in first-line treatment of metastatic colorectal cancer : results of the Australasian Gastrointestinal Trials Group Randomized Phase III MAX Study", J Clin Oncol, 28, pp.3191~3198 (2010)
23. Loupakis F, "Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer", N Engl J Med, 371, pp.1609~1618 (2014)
24. Giantonio BJ, "Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin(FOLFOX4)for previously treated metastatic colorectal cancer : results from the Eastern Cooperative Oncology Group Study E3200", J Clin Oncol, 25, pp.1539~1544 (2007)
25. Bennouna J, "Continuation of bevacizumab after first progression in metastatic colorectal cancer(ML18147) : a randomised phase 3 trial", Lancet Oncol, 14, pp.29~37 (2013)
26. Van Cutsem E, "Addition of aflibercept to fluorouracil, leucovorin, and irinotecan improves survival in a phase III randomized trial in patients with metastatic colorectal cancer previously treated with an oxaliplatin-based regimen", J Clin Oncol, 30, pp.3499~3506 (2012)
27. Tabernero J, "Ramucirumab versus placebo in combination with second-line FOLFIRI in patients with metastatic colorectal carcinoma that progressed during or after first-line therapy with bevacizumab, oxaliplatin, and a fluoropyrimidine(RAISE) : a randomised, double-blind, multicentre, phase 3 study", Lancet Oncol, 16, pp.499~508 (2015)
28. Grothey A, "Regorafenib monotherapy for previously treated metastatic colorectal cancer(CORRECT) : an international, multicentre, randomised, placebo-controlled, phase 3 trial", Lancet, 381, pp.303~312 (2013)
29. Jonker DJ, "Cetuximab for the treatment of colorectal cancer", N Engl J Med, 357, pp.2040~2048 (2007)
30. Karapetis CS, "K-ras mutations and benefit from cetuximab in advanced colorectal cancer", N Engl J Med, 359, pp.1757~1765 (2008)
31. Bokemeyer C, "FOLFOX4plus cetuximab treatment and RAS mutations in colorectal cancer", Eur J Cancer, 51, pp.1243~1252 (2015)
32. Douillard JY, "Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer", N Engl J Med, 369, pp.1023~1034 (2013)
33. Van Cutsem E, "Fluorouracil, leucovorin, and irinotecan plus cetuximab treatment and RAS mutations in colorectal cancer", J Clin Oncol, 33, pp.692~700 (2015)
34. Misale S, "Resistance to anti-EGFR therapy in colorectal cancer : from heterogeneity to convergent evolution", Cancer Discov, 4, pp.1269~1280 (2014)
35. Maughan TS, "Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer : results of the randomised phase 3 MRC COIN trial", Lancet, 377, pp.2103~2114 (2011)
36. Tveit KM, "Phase III trial of cetuximab with continuous or intermittent fluorouracil, leucovorin, and oxaliplatin(Nordic FLOX)versus FLOX alone in first-line treatment of metastatic colorectal cancer : the NORDIC-VII study", J Clin Oncol, 30, pp.1755~1762 (2012)
37. Van Cutsem E, "Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer", N Engl J Med, 360, pp.1408~1417 (2009)
38. Van Cutsem E, "Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer : updated analysis of overall survival according to tumor KRAS and BRAF mutation status", J Clin Oncol, 29, pp.2011~2019 (2011)
39. Douillard JY, "Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin(FOLFOX4)versus FOLFOX4alone as first-line treatment in patients with previously untreated metastatic colorectal cancer : the PRIME study", J Clin Oncol, 28, pp.4697~4705 (2010)
40. Stintzing S, "FOLFIRI plus cetuximab versus FOLFIRI plus bevacizumab for metastatic colorectal cancer(FIRE-3) : a post-hoc analysis of tumour dynamics in the final RAS wild-type subgroup of this randomised open-label phase 3 trial", Lancet Oncol, 17, pp.1426~1434 (2016)
41. Schwartzberg LS, "PEAK : a randomized, multicenter phase II study of panitumumab plus modified fluorouracil, leucovorin, and oxaliplatin(mFOLFOX6)or bevacizumab plus mFOLFOX6 in patients with previously untreated, unresectable, wild-type KRAS exon 2 metastatic colorectal cancer", J Clin Oncol, 32, pp.2240~2247 (2014)
42. Venook AP, "Effect of first-line chemotherapy combined with cetuximab or bevacizumab on overall survival in patients with KRAS wild-type advanced or metastatic colorectal cancer : a randomized clinical trial", JAMA, 317, pp.2392~2401 (2017)
43. Arnold D, "Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials", Ann Oncol, 28, pp.1713~1729 (2017)
44. Tejpar S, "Prognostic and predictive relevance of primary tumor location in patients with RAS wild-type metastatic colorectal cancer : retrospective analyses of the CRYSTAL and FIRE-3 trials", JAMA Oncol, 3, pp.194~201 (2017)
45. Morgan CT, "Systemic chemotherapy for resectable hepatic colorectal metastases: adjuvant, neoadjuvant, or not at all?", Curr Surg Rep, 2, pp.52~ (2014)
46. Portier G, "Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases : FFCD ACHBTH AURC 9002 trial", J Clin Oncol, 24, pp.4976~4982 (2006)
47. Mitry E, "Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer : a pooled analysis of two randomized trials", J Clin Oncol, 26, pp.4906~4911 (2008)
48. Primrose J, "Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis : the New EPOC randomised controlled trial", Lancet Oncol, 15, pp.601~611 (2014)
49. Chun YS, "Management of chemotherapy-associated hepatotoxicity in colorectal liver metastases", Lancet Oncol, 10, pp.278~286 (2009)
50. Karoui M, "Influence of preoperative chemotherapy on the risk of major hepatectomy for colorectal liver metastases", Ann Surg, 243, pp.1~7 (2006)
51. Gruenberger T, "Bevacizumab plus mFOLFOX-6 or FOLFOXIRI in patients with initially unresectable liver metastases from colorectal cancer : the OLIVIA multinational randomised phase II trial", Ann Oncol, 26, pp.702~708 (2015)
52. Blazer DG 3rd, "Pathologic response to preoperative chemotherapy : a new outcome end point after resection of hepatic colorectal metastases", J Clin Oncol, 26, pp.5344~5351 (2008)
53. Folprecht G, "Survival of patients with initially unresectable colorectal liver metastases treated with FOLFOX", cetuximab or FOLFIRI, Ann Oncol, pp.2014, 25[DOI]
54. Ye LC, "Randomized controlled trial of cetuximab plus chemotherapy for patients with KRAS wild-type unresectable colorectal liver-limited metastases", J Clin Oncol, 31, pp.1931~1938 (2013)
55. Tournigand C, "OPTIMOX1 : a randomized study of FOLFOX4 or FOLFOX7 with oxaliplatin in a stop-and-go fashion in advanced colorectal cancer : a GERCOR study", J Clin Oncol, 24, pp.394~400 (2006)
56. Simkens LH, "Maintenance treatment with capecitabine and bevacizumab in metastatic colorectal cancer(CAIRO3) : a phase 3 randomised controlled trial of the Dutch Colorectal Cancer Group", Lancet, 385, pp.1843~1852 (2015)
57. Hegewisch-Becker S, "Maintenance strategies after first-line oxaliplatin plus fluoropyrimidine plus bevacizumab for patients with metastatic colorectal cancer(AIO 0207) : a randomised, non-inferiority, open-label, phase 3 trial", Lancet Oncol, 16, pp.1355~1369 (2015)
58. Cancer Genome Atlas Network, "Comprehensive molecular characterization of human colon and rectal cancer", Nature, 487, pp.330~337 (2012)
59. Sanz-Garcia E, "BRAF mutant colorectal cancer : prognosis, treatment, and new perspectives", Ann Oncol, 28, pp.2648~2657 (2017)
60. Van Cutsem E, "ESMO consensus guidelines for the management of patients with metastatic colorectal cancer", Ann Oncol, 27, pp.1386~1422 (2016)
61. Kopetz S, "Phase II pilot study of vemurafenib in patients with metastatic BRAF-mutated colorectal cancer", J Clin Oncol, 33, pp.4032~4038 (2015)
62. Greally M, "HER2 : an emerging target in colorectal cancer", Curr Probl Cancer, 42, pp.560~571 (2018)
63. Sartore-Bianchi A, "Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12", 13 wild-type, HER2-positive metastatic colorectal cancer(HERACLES) : a proofof-concept, multicentre, open-label, phase 2 trial, 2016, pp.17, 738~746
64. Le DT, "PD-1 blockade in tumors with mismatch-repair deficiency", N Engl J Med, 372, pp.2509~2520 (2015)
65. Overman MJ, "Durable clinical benefit with nivolumab plus ipilimumab in DNA mismatch repair-deficient", microsatellite instability-high metastatic colorectal cancer, 2018, pp.36, 773~779
66. Lee JJ, "Recent advances in the clinical development of immune checkpoint blockade therapy for mismatch repair proficient(pMMR)", non-MSI-H metastatic colorectal cancer, 2018, pp.17, 258~273

관련 논문AI추천